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Activation of melanocortin-4 receptor (MC4R) by insulin sensitive neurons is a central mechanism in body weight regulation,
and genetic variants in the MC4R gene (e.g., rs17782313) are associated with obesity. By using magnetoencephalography, we
addressed whether rs17782313 aﬀects the cerebrocortical insulin response. We measured the cerebrocortical insulin response by
using magnetoencephalography in a hyperinsulinemic euglycemic clamp (versus placebo) in 51 nondiabetic humans (26 f/25 m,
age 35 ±3y e a r s ,B M I2 8±1kg/m 2). The C-allele of rs17782313 was minor allele (frequency 23%), and the genotype distribution
(TT 30, TC 19, CC 2) was in Hardy-Weinberg-Equilibrium. Insulin-stimulated cerebrocortical theta activity was decreased in the
presence of the C-allele (TT 33 ± 16fT; TC/CC −27 ± 20fT; P = .023), and this eﬀect remained signiﬁcant after adjusting for
BMI and peripheral insulin sensitivity (P = .047). Cerebrocortical theta activity was impaired in carriers of the obesity risk allele.
Therefore, cerebral insulin resistance may contribute to the obesity eﬀect of rs17782313.
1.Introduction
Melanocortin receptors (MC3R and MC4R) have been dem-
onstrated in multiple brain regions including the hypothala-
mus [1, 2] and represent critical components of a regulating
system for body weight and energy homeostasis. Both dis-
ruption of MC4R in mice [3] and mutations in the coding
region of human MC4R result in a severely obese phenotype
[4, 5]. Another relatively rare (2–4%) polymorphism in
the MC4R coding region has been reported to protect
from obesity [6]. In recent genome-wide association studies
(GWAS) also common genetic variants near the MC4R gene
were associated with BMI [7], waist circumference, and
insulin resistance [8].
Melanocortin receptors receiveinformation from POMC
and AgRP neurons about the nutritional and metabolic
status. While POMC derivates like alpha-MSH and beta-
MSH stimulate melanocortin receptors, agouti-related pro-
tein (AgRP) is known to be a natural antagonist. As leptin
and insulin activate POMC neurons and suppress AgRP
neurons,bothhormonescontributetotheregulationofbody
weight and energy homeostasis via melanocortin receptors,
and knock-out of MC4R results in decreased action of leptin
and insulin in the brain [9].
We previously established a method to measure acute
insulin responses in the human brain by combining magne-
toencephalography (MEG) and the hyperinsulinemic eug-
lycemic clamp technique [10]. In this study, we observed
that cerebral insulin resistance is associated with obesity in
humans and therefore speculated that a decreased insulin
response of the brain might contribute to obesity caused by
geneticalterationsofMC4R. Asrs17782313hadthestrongest2 Journal of Obesity
BMI signal in a GWAS study [7], we studied the eﬀect of
this single nucleotide polymorphism (SNP) on the insulin
response of the brain.
2.Methods
2.1. Human Subjects and Experimental Design. We deter-
mined rs17782313 in the MC4R gene region in 51 subjects
who were healthy by self-report and clinical examination
and presented nondiabetic in an oral glucose tolerance test
according to WHO/ADA criteria. Detailed characteristics of
these subjects are given in Table 1.
2.2. Hyperinsulinemic Euglycemic Clamp and Saline Experi-
ment with Measurement of Cerebrocortical Activity by Magne-
toencephalography (MEG). To measure the insulin response
of the brain, these subjects participated in an insulin and
ap l a c e b o( =saline) experiment in random order on two
diﬀerent days approximately 1 to 2 weeks apart. Each
experiment started at approximately 7.00 a.m. and consisted
of a 30-minute baseline period, and a 2-step hyperinsu-
linemic euglycemic clamp or saline infusion. To maintain
blood glucose at baseline levels a standard hyperinsulinemic
euglycemic clamp protocol was followed. The details of the
clamp procedures and the neurophysiologic measurements
performed by MEG have been described in [10]. Here we
used the change of spontaneous cortical beta and theta activ-
ity during insulin infusion (corrected for placebo derived
changes) to quantify the cerebrocortical response to insulin.
Beta and theta activity were extracted from spontaneous
cortical activity by using fast Fourier transformation.
2.3. Analytical Procedures and Measurement of Body Fat.
Plasma glucose was determined during the OGTT using the
glucose oxidase method (YSI, Yellow Springs Instruments,
Yellow Springs, CO, USA). Blood glucose was determined
in the clamp experiments by a HemoCue blood glucose
photometer (HemoCue AB, Aengelholm, Sweden). Plasma
insulin levels were determined by microparticle enzyme
immunoassay (Abbott Laboratories, Tokyo, Japan). Body
composition was measured by bioelectrical impedance anal-
ysis (BIA-101A, RJL Systems, Detroit, Michigan, USA) and
expressed as percent body fat.
2.4. Genotyping. For genotyping, DNA was isolated from
whole blood using a commercial DNA isolation kit (Nucle-
oSpin; Macherey & Nagel, D¨ uren, Germany). The SNPs
were genotyped using the TaqMan assay (Applied Biosys-
tems, Foster City, CA). The TaqMan genotyping reaction
was ampliﬁed on a GeneAmp PCR system 7000 (Applied
Biosystems) (50◦Cf o r2m i n u t e s ,9 5 ◦Cf o r1 0m i n u t e s ,
followed by 40 cycles of 95◦C for 15 seconds and 60◦Cf o r
1 minute), and ﬂuorescence was detected on an ABI Prism
sequence detector (AppliedBiosystems). Quality control was
performed as reported in [11].
2.5. Statistical Analysis. For statistical analyses, MEG data
of the saline experiment were subtracted from data of the
Table 1: Subject characteristics and eﬀect of rs17782313on obesity
measures and peripheral insulin sensitivity.
Genotype TT TC/CC P
N (%) 30 (59%) 21 (41%) —
Gender (F/M) 14/16 12/9 —
Age (years) 33 ± 23 8 ±3. 1 4
Weight (kg) 81.4 ± 3.48 3 .9 ±3.6. 4 7 ∗
BMI (kg/m2)2 7 .1 ± 0.92 8 .4 ±1.0. 6 2 ∗
Body fat (%) 27.1 ± 1.63 0 .5 ±1.9. 5 7 ∗
Waist circumference
(cm) 92 ± 39 5 ±3. 3 4 ∗
Fasting plasma glucose
(mmol/L) 4.9 ± 0.15 .1 ±0.1. 3 5 ∗
2H rg l u c o s e
(mmol/L)∗∗ 6.1 ± 0.36 .6 ±0.4. 5 1 ∗
Insulin sensitivity index
(µmol·kg/−1·pM−1)∗∗∗ 0.074 ± 0.009 0.062 ±0.010 .67∗
M ± SE; ∗adjusted for age and gender; ∗∗OGTT; ∗∗∗Hyperinsulinemic
euglycemicclamp.
insulin experiment to correct for potential placebo eﬀects
and daytime variation. The change of the investigated MEG
parameters from basal to the second step of the clamp was
considered to indicate the total insulin eﬀect and was used in
further analyses.
Unless otherwise stated, data are means ± SE. Non-
normally distributed variables (Shapiro-Wilk W test) were
logarithmically transformed. To adjust for covariates and
to identify independent relationships, we performed linear
multipleregression analyses. In general,aP valueof<.05was
considered to indicate statistical signiﬁcance. As we studied
insulin-inducedchangesinbetaandthetaactivity,correction
for multiple comparisons requires an alpha level of 0.025
instead of 0.05 for the primary analysis of MEG data. Due
to the very low number of CC carriers, determination of
a per allele risk as suggested by another study [7]w a sn o t
possible. Therefore, TC and CC carriers were treated as one
group and compared with wild-type carriers in all further
analyses. Forall statisticalanalyses, thesoftware packageJMP
(SAS Institute, Cary, NC) was used.
2.6. Ethical Statement. The study protocol was approved by
the Ethical Committee of the University of T¨ ubingen and
informed written consent had been obtained from each
subject prior to the studies. The whole study protocol has
been designed in accordance with the declarationof Helsinki
(1964). Furthermore, we certify that all applicable institutio-
nal and governmental regulations concerning the ethical use
of human volunteers were followed during the research.
3.Results
3.1. Genotype Data and Body Weight Eﬀect of rs17782313.
The genotype distribution (TT 30, TC 19, and CC 2) was
in Hardy-Weinberg-Equilibrium, and the minor C-allele
had a frequency of 23%. Carriers of the rare allele wereJournal of Obesity 3
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Figure 1: Insulin eﬀect on theta activity in the genotype groups: in
subjects carrying the rare allele of rs17782313 in the homozygous
(TC) or the heterozygous form (CC), the eﬀect of insulin on theta
activity was signiﬁcantly reduced as compared to carriers of the
wild-type allele (TT) (P = .023). The diamonds show the means
of each group (horizontal line) and the conﬁdence intervals of
the means (upper and lower point). The eﬀect of the genotype
remained signiﬁcant after adjusting for BMI (P = .038) and also
afteradjustingforBMIandperipheralinsulinsensitivity(P = .047).
2.5kg heavier, displayed a slightly increased BMI, waist cir-
cumference, and body fat as compared to the wild-type
carriers;however,alltheseeﬀectsfailedstatisticalsigniﬁcance
(Table 1). According to the weight eﬀect, peripheral insulin
sensitivity was reduced in CC carriers.
3.2. Cerebrocortical Insulin Resistance in Carriers of
rs17782313. Regarding the eﬀect of insulin on the cerebral
cortex, we observed a decreased eﬀect on theta activity
(Figure 1) in presence of the C-allele (TT 33 ± 16 fT, TC/CC
−27±20 fT, P = .023).This association remained signiﬁcant
after adjusting for BMI (P = .038) and also after adjusting
for BMI and peripheral insulin sensitivity (P = .047). In
contrast to theta activity, there was no signiﬁcant reduction
ofinsulin-mediated betaactivity byrs17782313(TT3.0±3.2
fT, TC/CC −1.3 ± 4.1f T ,P = .41).
4.Discussion
Our data demonstrate that the insulin response of the brain
measuredbymagnetoencephalography(MEG)isdiminished
in carriers of rs17782313. From a mechanistical point of
view, these data support the idea that a decreased insulin
response of the brain is a pathogenic factor that contributes
to the eﬀectofthispolymorphismon obesity.However,asso-
ciation data have some limitations, as they cannot deﬁnitely
prove the direction of an eﬀect and provide only indirect
information on the underlying mechanisms. Here, it is clear
that the primary site of the obesity eﬀect must be located in
t h eb r a i n ,a sM C 4 Ri sh i g h l ye x p r e s s e di nt h eb r a i nb u tn o t
in peripheral tissues [1]. To get the best possible information
from our data, we performed multiple regression models to
adjust the cerebral eﬀect of the polymorphism for obesity
and for peripheral insulin resistance. As the SNP eﬀect on
the cerebrocortical insulin response remained signiﬁcant,
our data suggest that rs17782313 directly alters the insulin
response of the brain.
In contrast to the cerebrocortical eﬀect, the diﬀerences
in obesity measures and metabolic parameters between the
genotype group were not signiﬁcant, though the eﬀect size
seems comparable to previous reports on MC4R polymor-
phisms [7, 8]. One explanation for the lack of signiﬁcance
in these parameters is that altered brain function is likely to
be the primary eﬀect of the MC4R SNP, while obesity and
metabolic alterations are secondary. Furthermore, BMI and
waist circumference have limited accuracy in small sample
sizes.
We have previously demonstrated reduced insulin re-
sponses of beta and theta activities in obese humans [10].
Notably, the eﬀect of rs17782313 occurred only in the theta
activity band, while there was no eﬀect on beta activity. In
contrast, we observed that variation in the FTO and IRS-
1 gene is associated with a reduction of insulin-mediated
beta activity, while theta activity is not aﬀected [10, 12].
Furthermore, we reported that beta and theta activities
are diﬀerently aﬀected by aging [13] and suggested that
these parameters may represent diﬀerent brain structures
and functions and their responses to insulin. Therefore,
these data suggest that suppressed cerebral insulin eﬀects
by genetic variation in FTO and aging involve diﬀerent
mechanisms than variation in the MC4R gene.
It is interesting to note, that theta activity is mainly
generatedinthehippocampus[14].Furthermore,thehippo-
campushas beenshown to contributeto food-related reward
in obese women [15]. Additionally, theta activity has been
attributed to locomotor activity and voluntary movements
[16]. Therefore, a decreased response of theta activity to
insulin by the obesity risk allele of rs17782313 may indicate
increased food reward and decreased locomotor activity as
possible mechanisms that contribute to the development of
obesity in these subjects.
5.Conclusions
Genetic variation in MC4R leads to an impaired insulin
response in theta activity in the human brain. Though
speciﬁc suggestionsonunderlying brainfunctions arespecu-
lative, our data support that these functions may be diﬀerent
from alterations observed with aging and variation in the
FTO gene.
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